RANBAXY SUCCESSFULLY INVALIDATES ATORVASTATIN PATENT IN AUSTRIA

Ranbaxy Laboratories Limited announced on Wednesday that a five-judge panel of the Supreme Patent and Trademark Board of Austria (OPM) has unanimously affirmed an earlier ruling of the Austrian Patent Office, invalidating claims 13 (all claims sought by Ranbaxy to be invalidated) of Pfizer's Austrian Patent AT 207896, covering Atorvastatin calcium (Lipitor).

Ag-ip-news.com (http://www.ag-ip-news.com/GetArticle.asp?Art_ID=2986&lang=en)